Drug · ALS · ALS · Verified drug
Riluzole (Rilutek) structure · mechanism
Riluzole (Rilutek) 2D structure
- Role
- Drug
- Mechanism class
- ALS
- Parent scaffold
- Aminobenzothiazole core
- Indication
- ALS — survival modest benefit · FDA/EMA
- Structure source
- Catalog seed
- FDA / EMA
- FDA/EMA
- ClinicalTrials.gov
- riluzole ALS
- Regulatory status
- Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov
Hand-written analysis
Mechanism
릴루졸은 글루타메이트 전달을 줄이는 벤조티아졸로 ALS 생존을 소폭 연장합니다. 간효소 모니터링이 필요합니다. 질병조절 폭은 제한적입니다.
Medicinal chemistry
트리플루오로메톡시 벤조티아졸입니다. 에다라본(피라졸론)과 표적이 다릅니다.
Indication · context
ALS 경구 표준 중 하나입니다. 승인·철회 브리프와 함께 읽습니다.
SMILES
Nc1nc2cc(OC(F)(F)F)ccc2s1Tags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.